SCHEMBL4411176

SCHEMBL4411176

Fc1cc(NCC2C3CN(Cc4ccc(OC(F)(F)F)cc4)CC23)ccc1N1CCOCC1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 3/20 0.44
KCNH2 Q12809 1/20 0.44
MAPT P10636 2/20 0.42
ALDH1A1 P00352 1/20 0.42
GLA P06280 1/20 0.42
GAA P10253 2/20 0.42
TEAD1 P28347 3/20 0.41
DRD4 P21917 3/20 0.40
DRD2 P14416 2/20 0.40
DRD3 P35462 2/20 0.40
CHRM4 P08173 1/20 0.40
EPHX2 P34913 4/20 0.40
BCR P11274 2/20 0.39
BCHE P06276 1/20 0.39
ACHE P22303 1/20 0.39
BACE1 P56817 1/20 0.39
PKM P14618 1/20 0.39
MAPK1 P28482 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4415737 0.92 P2RX3 (0.39) ABL1KCNH2ALDH1A1GAAMAPK1
SCHEMBL4412004 0.91 KCNH2 (0.46) ABL1KCNH2MAPTALDH1A1GLA
SCHEMBL4415239 0.89 SMN1; SMN2 (0.46) MAPTDRD4ACHEBACE1MAPK1
SCHEMBL4414914 0.88 HIF1A (0.47) ALDH1A1GAAEPHX2
SCHEMBL4412123 0.88 L3MBTL1 (0.41) MAPTALDH1A1GAAMAPK1
SCHEMBL4412370 0.88 L3MBTL1 (0.44) MAPTGAA
SCHEMBL4413699 0.88 GAA (0.48) MAPTALDH1A1GAA
SCHEMBL4423662 0.88 CNR2 (0.42) MAPTALDH1A1GAADRD4MAPK1
SCHEMBL6506969 0.88 ALDH1A1 (0.50) MAPTALDH1A1GAA
SCHEMBL4552124 0.87 P2RX3 (0.43) MAPTALDH1A1GAAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1680124-B1 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PROD INC (US) 2017-05-31 EP claimed
EP-1680124-A4 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PROD INC (US) 2009-05-13 EP claimed
JP-2007508374-A 2007-04-05 JP claimed
EP-1680124-A2 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS Pfizer Products Incorporated (US) 2006-07-19 EP claimed
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC. 2005-05-05 US claimed
WO-2005037216-A2 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PRODUCTS INC. (US) 2005-04-28 WO claimed
EP-1680124-B1 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PROD INC (US) 2017-05-31 EP disclosed
US-7473787-B2 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC (US) 2009-01-06 US disclosed
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC. 2005-05-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors SLC6A5, SLC1A5, SLC6A3 ABL1 1605/4885KCNH2 426/4885MAPT 1368/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.